Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate

• Ken Liu,
• Ken Liu,
• Ken Liu,
• Jinbiao Chen,
• Yang Zhao,
• Jade Boland,
• Ka Ka Ting,
• Glen Lockwood,
• Catriona McKenzie,
• James Kench,
• Mathew A. Vadas,
• Mathew A. Vadas,
• Jennifer R. Gamble,
• Jennifer R. Gamble,
• Geoffrey W. McCaughan,
• Geoffrey W. McCaughan,
• Geoffrey W. McCaughan

Affiliations

Ken Liu

AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia

Ken Liu

Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Ken Liu

Centenary Institute, University of Sydney, Sydney, NSW, Australia

Jinbiao Chen

Centenary Institute, University of Sydney, Sydney, NSW, Australia

Yang Zhao

Centenary Institute, University of Sydney, Sydney, NSW, Australia

Jade Boland

Centenary Institute, University of Sydney, Sydney, NSW, Australia

Ka Ka Ting

Centenary Institute, University of Sydney, Sydney, NSW, Australia

Glen Lockwood

Biogerontology Group, ANZAC Research Institute, Sydney, NSW, Australia

Catriona McKenzie

New South Wales Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

James Kench

New South Wales Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

Mathew A. Vadas

Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Mathew A. Vadas

Centenary Institute, University of Sydney, Sydney, NSW, Australia

Jennifer R. Gamble

Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Jennifer R. Gamble

Centenary Institute, University of Sydney, Sydney, NSW, Australia

Geoffrey W. McCaughan

AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia

Geoffrey W. McCaughan

Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Geoffrey W. McCaughan

Centenary Institute, University of Sydney, Sydney, NSW, Australia